With Positive Data, BridgeBio’s Acoramidis Will Take Share

With Positive Data, BridgeBio’s Acoramidis Will Take Share

What will the market split look like if BridgeBio Pharma’s acoramidis is approved in 2024 as a challenger to Pfizer’s tafamidis?

Report Date :
12/14/2023
Topic :
BridgeBio Pharma Inc.
Source Silos :
  1. Cardiologists and their team members
  2. Cardiology medication sales professionals
  3. Third-party payers
  4. Industry specialists
Sector :
Healthcare
Companies :
ALNY, AZN, BBIO, IONS, PFE, SOBI.ST
Industry :
Biotechnology

With Positive Data, BridgeBio’s Acoramidis Will Take Share PDF